TRANSDERMAL DRUG DELIVERY SYSTEMS
... adverse reactions may be due to a formulation additive (excipient) and not necessarily an active compound. it is well known that the pressure sensitive adhesive used to produce intimate contact with the skin is more often the source of cutaneous reactivity & not the drug. many of the inactive ingred ...
... adverse reactions may be due to a formulation additive (excipient) and not necessarily an active compound. it is well known that the pressure sensitive adhesive used to produce intimate contact with the skin is more often the source of cutaneous reactivity & not the drug. many of the inactive ingred ...
Krisztina Boda - UK-QSAR
... Retro-synthetic knowledge base Fragmenting MDDR Synthetic knowledge base Structure generation in SynSPROUT Example Future work ...
... Retro-synthetic knowledge base Fragmenting MDDR Synthetic knowledge base Structure generation in SynSPROUT Example Future work ...
Predicting Drug Metabolism - Cambridge Repository
... apply to certain biomolecules (mainly metabolic enzymes) and/or to specific metabolic reactions, while global models are in principle applicable to diverse biological systems (i.e. to any metabolic enzyme and biotransformation) and to most small organic compounds. The goal of many metabolism softwar ...
... apply to certain biomolecules (mainly metabolic enzymes) and/or to specific metabolic reactions, while global models are in principle applicable to diverse biological systems (i.e. to any metabolic enzyme and biotransformation) and to most small organic compounds. The goal of many metabolism softwar ...
Barbiturates
... – The amount of the drug influences its effect • Its intensity • The kind of effect it has on the person ...
... – The amount of the drug influences its effect • Its intensity • The kind of effect it has on the person ...
MIC - Physiologie et Thérapeutique Ecole Véto Toulouse (ENVT)
... cefquinome was achieved in horses using a jet nebulizer, but cefquinome was not detectable after 4 h in the majority of horses – This is likely true for any drug that was not specifically developed for inhalation (e.g. dexamethasone) because pulmonary absorption is very fast due to a very high blood ...
... cefquinome was achieved in horses using a jet nebulizer, but cefquinome was not detectable after 4 h in the majority of horses – This is likely true for any drug that was not specifically developed for inhalation (e.g. dexamethasone) because pulmonary absorption is very fast due to a very high blood ...
Antimicrobial drugs in Respiratory Infection
... Spectrum: slightly less active than ciprofloxacin and ofloxacin against gram-negative bacteria but have greater activity against gram-positive cocci, including S pneumoniae and some strains of enterococci and methicillin-resistant Staphylococcus aureus (MRSA). The broadest-spectrum fluoroquinolones ...
... Spectrum: slightly less active than ciprofloxacin and ofloxacin against gram-negative bacteria but have greater activity against gram-positive cocci, including S pneumoniae and some strains of enterococci and methicillin-resistant Staphylococcus aureus (MRSA). The broadest-spectrum fluoroquinolones ...
| Barriers to new drug development in respiratory disease Peter J. Barnes
... The challenges of drug discovery Very high attrition rates during the process of drug discovery are making it more difficult and more expensive to bring new drugs, particularly new chemical entities, to market. For every approved new drug there are ∼10 000 chemicals with a marked loss of compounds a ...
... The challenges of drug discovery Very high attrition rates during the process of drug discovery are making it more difficult and more expensive to bring new drugs, particularly new chemical entities, to market. For every approved new drug there are ∼10 000 chemicals with a marked loss of compounds a ...
chapter 1 - New Age International
... pharmacologic activity (d) Hepatic metabolism and renal excretion are the two most important mechanisms involved ...
... pharmacologic activity (d) Hepatic metabolism and renal excretion are the two most important mechanisms involved ...
Chapter 1: Literature review 1.1. Introduction
... good correlation with in vivo data, which is promising for this type of "expanded" cytotoxicity testing. However, some of the parameters were not very specific with regards to the endpoint that was examined. For example, rhodamine 123 was used to assess both mitochondrial effects and P-glycoprotein ...
... good correlation with in vivo data, which is promising for this type of "expanded" cytotoxicity testing. However, some of the parameters were not very specific with regards to the endpoint that was examined. For example, rhodamine 123 was used to assess both mitochondrial effects and P-glycoprotein ...
STATUS OF FIXED DOSE DRUG COMBINATION IN ANTIDIABETIC DRUG
... of long term Monotherapy Target end point: HbA1C level < 7 mg % (UKPDS-49) Monotherapy for 3 years = Success rates 50% Monotherapy for 9 years = Success rates 30% (Turner et al.,1999) Patients not achieving or maintaining the target would be candidates for multiple oral antidiabetic therapy and/or i ...
... of long term Monotherapy Target end point: HbA1C level < 7 mg % (UKPDS-49) Monotherapy for 3 years = Success rates 50% Monotherapy for 9 years = Success rates 30% (Turner et al.,1999) Patients not achieving or maintaining the target would be candidates for multiple oral antidiabetic therapy and/or i ...
1990: Postgraduate specialization in Pediatrics, University of Rome
... and on retinoids in the apoptotic pathways in oncology, in particular neuroblastoma. Since 1998 I have focused on Glutathione transferases, a family of enzymes involved in cell detoxification and in the control of the programmed cell death. This work has concentrated on the role of those enzymes in ...
... and on retinoids in the apoptotic pathways in oncology, in particular neuroblastoma. Since 1998 I have focused on Glutathione transferases, a family of enzymes involved in cell detoxification and in the control of the programmed cell death. This work has concentrated on the role of those enzymes in ...
Jan p. 2 - Epocrates
... found that, in 43% of the cases, pharmacists responded to the DDI alert by using their own references, an indication that the alerts were not providing sufficient or high-quality information about the DDI. Segments of the healthcare community have increasingly embraced PDAs because of their compactn ...
... found that, in 43% of the cases, pharmacists responded to the DDI alert by using their own references, an indication that the alerts were not providing sufficient or high-quality information about the DDI. Segments of the healthcare community have increasingly embraced PDAs because of their compactn ...
Combinatorial chemistry: A novel method in drug discovery and its
... starting material. Member of building block should reflect broad array of physiological properties, e.g. functionality, charge, confirmation, etc. Screening An essential element of the combinatorial discovery process is that one must be able to extract the information made available by library. This ...
... starting material. Member of building block should reflect broad array of physiological properties, e.g. functionality, charge, confirmation, etc. Screening An essential element of the combinatorial discovery process is that one must be able to extract the information made available by library. This ...
PowerPoint_Chapter1
... name of a drug during this process? Answer: A generic drug name is assigned to a medical molecule by a government agency and is used during Phase I, II, and III clinical trials. Near the end of Phase III, a brand name is assigned by the company that will manufacture and sell the drug. Question 2: Wh ...
... name of a drug during this process? Answer: A generic drug name is assigned to a medical molecule by a government agency and is used during Phase I, II, and III clinical trials. Near the end of Phase III, a brand name is assigned by the company that will manufacture and sell the drug. Question 2: Wh ...
Read More… - Envisia Therapeutics
... technology to create particle-based ocular therapeutics that can deliver both small and large molecules in multiple formats. Envisia’s lead product, ENV515, is a marketed prostaglandin analogue that uses a proprietary, fully biodegradable PRINT particle formulation to provide sustained intraocular p ...
... technology to create particle-based ocular therapeutics that can deliver both small and large molecules in multiple formats. Envisia’s lead product, ENV515, is a marketed prostaglandin analogue that uses a proprietary, fully biodegradable PRINT particle formulation to provide sustained intraocular p ...
Effect of drug type on the degradation rate of PLGA
... groups and the drug release parameters. Kiortsis et al. [18] have shown that the % release of drugs from cellulosic polymers, at a fixed time point, depends on the drug solubility in water; it seems reasonable that hydrophilic drugs with high solubility may increase the rate of water diffusion into ...
... groups and the drug release parameters. Kiortsis et al. [18] have shown that the % release of drugs from cellulosic polymers, at a fixed time point, depends on the drug solubility in water; it seems reasonable that hydrophilic drugs with high solubility may increase the rate of water diffusion into ...
ROUTING SLIP GENERATED BY:
... spokesman Greg Aiello, quoted in a Los Angeles Times article stated that “the purpose is to protect our players who operate in a very unique and stressful environment”. Aiello also said “because of the research that’s out there on ephedra, the commissioner [Paul Tagliabue] has reached the conclusion ...
... spokesman Greg Aiello, quoted in a Los Angeles Times article stated that “the purpose is to protect our players who operate in a very unique and stressful environment”. Aiello also said “because of the research that’s out there on ephedra, the commissioner [Paul Tagliabue] has reached the conclusion ...
NON-INVASIVE TRANSDERMAL ULTRASOUND WATCH
... microcontroller and other equipments which connected to at least one LCD screen with at least one button control to let the user choose time and doses needed to be transferred into human skin, the whole system will be packaged on a printed circuit board with a power supply to drive the whole system ...
... microcontroller and other equipments which connected to at least one LCD screen with at least one button control to let the user choose time and doses needed to be transferred into human skin, the whole system will be packaged on a printed circuit board with a power supply to drive the whole system ...
alcohol - Michael Cohen Psychologist
... environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterised by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortion in thinking, most notable denial. ...
... environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterised by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortion in thinking, most notable denial. ...
FORMULATION AND EVALUATION OF DICLOFANAC POTASSIUM ETHOSOMES Research Article VIJAYAKUMAR M.R., ABDUL HASAN SATHALI A , ARUN K.
... higher cumulative percentage of drug permeation (60.37±5%) and more skin retention (619.60±18µg/cm2) after 12 hours than the other formulations. Scanning electron microscopy confirmed the three dimensional nature of ethosomes. Dynamic light scattering technique proved that the eth ...
... higher cumulative percentage of drug permeation (60.37±5%) and more skin retention (619.60±18µg/cm2) after 12 hours than the other formulations. Scanning electron microscopy confirmed the three dimensional nature of ethosomes. Dynamic light scattering technique proved that the eth ...
Successes, Threats, Challenges and Opportunities of Early
... Desired therapeutic effect (Other effects) Secondary effects Beneficial, deleterious or neutral ...
... Desired therapeutic effect (Other effects) Secondary effects Beneficial, deleterious or neutral ...
Drug design
Drug design, sometimes referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is often referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the biomolecular target is known as structure-based drug design. In addition to small molecules, biopharmaceuticals and especially therapeutic antibodies are an increasingly important class of drugs and computational methods for improving the affinity, selectivity, and stability of these protein-based therapeutics have also been developed.The phrase ""drug design"" is to some extent a misnomer. A more accurate term is ligand design (i.e., design of a molecule that will bind tightly to its target). Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, side effects, etc., that first must be optimized before a ligand can become a safe and efficacious drug. These other characteristics are often difficult to predict with rational design techniques. Nevertheless, due to high attrition rates, especially during clinical phases of drug development, more attention is being focused early in the drug design process on selecting candidate drugs whose physicochemical properties are predicted to result in fewer complications during development and hence more likely to lead to an approved, marketed drug. Furthermore, in vitro experiments complemented with computation methods are increasingly used in early drug discovery to select compounds with more favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological profiles.